Literature DB >> 8631604

Overexpression of the proto-oncogene/translation factor 4E in breast-carcinoma cell lines.

B Anthony1, P Carter, A De Benedetti.   

Abstract

The expression of the proto-oncogene, translation factor elF-4E, was examined in breast-cell lines: 5 carcinomas and 2 normal. At the protein level, elF-4E was 10 times higher in the carcinoma lines than in normal cells, which is comparable to the level found in breast-cancer biopsies. The elevation appears to be due to increased transcription, since the elF-4E mRNA was correspondingly increased. These results demonstrate that cells isolated from naturally occurring breast carcinomas maintain an elevated expression of the factor. Turnover rates for elF-4E (mRNA and protein) were determined for normal and cancer cells. We found that elF-4e mRNA is relatively stable during an 8-hr incubation with Actinomycin D, but the half-life of the protein is fairly short (approximately 4.5 hr). This suggests that, in proliferating cells, elF-4E may be turning over rapidly, possibly to fine-tune the changes in translation rates which occur during the cell cycle.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8631604     DOI: 10.1002/(SICI)1097-0215(19960315)65:6<858::AID-IJC25>3.0.CO;2-Z

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  17 in total

1.  Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer.

Authors:  Christopher Johnson; Yuyan Han; Nathan Hughart; Jennifer McCarra; Gianfranco Alpini; Fanyin Meng
Journal:  Transl Gastrointest Cancer       Date:  2012-04-01

2.  Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression.

Authors:  B D Li; J C McDonald; R Nassar; A De Benedetti
Journal:  Ann Surg       Date:  1998-05       Impact factor: 12.969

3.  EIF4E over-expresses and enhances cell proliferation and cell cycle progression in nasopharyngeal carcinoma.

Authors:  Mengyan Wu; Yingxia Liu; Xiaoqing Di; Haixian Kang; Hua Zeng; Yi Zhao; Kangrong Cai; Tianyun Pang; Sen Wang; Yunhong Yao; Xinrong Hu
Journal:  Med Oncol       Date:  2013-01-01       Impact factor: 3.064

4.  Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome.

Authors:  Benjamin D L Li; Jeffrey S Gruner; Fleurette Abreo; Lester W Johnson; Herbert Yu; Soheir Nawas; John C McDonald; Arrigo DeBenedetti
Journal:  Ann Surg       Date:  2002-05       Impact factor: 12.969

5.  Contribution of eIF-4E inhibition to the expression and activity of heparanase in human colon adenocarcinoma cell line: LS-174T.

Authors:  Yu-Jie Yang; Ya-Li Zhang; Xu Li; Han-Lei Dan; Zhuo-Sheng Lai; Ji-De Wang; Qun-Ying Wang; Hai-Hong Cui; Yong Sun; Ya-Dong Wang
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

Review 6.  Eukaryotic initiation factor 4E-binding protein 1 (4E-BP1): a master regulator of mRNA translation involved in tumorigenesis.

Authors:  J Musa; M F Orth; M Dallmayer; M Baldauf; C Pardo; B Rotblat; T Kirchner; G Leprivier; T G P Grünewald
Journal:  Oncogene       Date:  2016-02-01       Impact factor: 9.867

Review 7.  Targeting Mnks for cancer therapy.

Authors:  Jinqiang Hou; Frankie Lam; Christopher Proud; Shudong Wang
Journal:  Oncotarget       Date:  2012-02

8.  Asthma and COPD - The C/EBP Connection.

Authors:  Nicola Miglino; Michael Roth; Michael Tamm; Peter Borger
Journal:  Open Respir Med J       Date:  2012-04-20

9.  Tissue microarray analysis of eIF4E and its downstream effector proteins in human breast cancer.

Authors:  Heather E Kleiner; Prasad Krishnan; Jesse Tubbs; Mark Smith; Carol Meschonat; Runhua Shi; Mary Lowery-Nordberg; Patrick Adegboyega; Marcia Unger; James Cardelli; Quyen Chu; J Michael Mathis; John Clifford; Arrigo De Benedetti; Benjamin D L Li
Journal:  J Exp Clin Cancer Res       Date:  2009-01-09

10.  Understanding and Targeting the Eukaryotic Translation Initiation Factor eIF4E in Head and Neck Cancer.

Authors:  Biljana Culjkovic; Katherine L Borden
Journal:  J Oncol       Date:  2009-12-13       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.